Cell Genesys San Diego Manufacturing Operation Acquired by Genzyme
Cell Genesys, Inc. and Genzyme Corp. announced that Genzyme has acquired Cell Genesys' manufacturing operation in San Diego, CA to support the growth of Genzyme's gene therapy programs. Under the terms of the agreement, Genzyme will pay Cell Genesys $3.2 million in cash for the assets contained in the 47,000 square-foot leased facilities. Most of the approximately 40 employees formerly employed by Cell Genesys have become Genzyme employees.
Genzyme plans to use the acquired assets and the new facilities to support its ongoing research and clinical trials, and to broaden the company's manufacturing capabilities related to both Adenovirus and Adeno-Associated Virus vectors. These vectors are used to deliver genes to the appropriate cells in patients.
The most advanced gene therapy program at Genzyme is an ongoing phase 2 clinical trial examining the safety and effectiveness of locally delivered Ad2/HIF-1 alpha, an engineered form of the HIF-1 alpha gene, for patients with peripheral arterial disease. Genzyme's experimental therapy is designed to promote the growth of new blood vessels and improve circulation in patients' limbs. The primary endpoint is change in the maximum amount of time a patient can walk on a treadmill without stopping due to pain from intermittent claudication.
The San Diego manufacturing operation was purchased by Cell Genesys from Chiron Corp. in 2001 for $4.8 million. Cell Genesys' decision to sell the operation was part of a strategic restructuring plan to focus its resources on its most advanced and most promising product development programs. The portfolio decisions resulted in a reduction of the company's manufacturing needs in the viral product area. The agreement between Cell Genesys and Genzyme includes an opportunity for Cell Genesys to have its lead oncolytic virus therapy product, CG0070, manufactured under contract with Genzyme. CG0070 is currently in a phase 1 trial for recurrent bladder cancer. Cell Genesys maintains its principal manufacturing operations for GVAX® cancer vaccines in Hayward, CA.
Other news from the department manufacturing
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
